On April 16, 2026 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cancer research and molecular diagnostics are increasingly constrained by fragmented workflows, variability in sample processing and the growing complexity of multi-omics data," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "At AACR (Free AACR Whitepaper), we are demonstrating how QIAGEN’s Sample to Insight portfolio helps standardize critical steps from sample preparation through data interpretation, enabling more consistent results, improved reproducibility and more confident insights from complex biological data."

At the AACR (Free AACR Whitepaper) Annual Meeting 2026, QIAGEN will showcase applications across key stages of the oncology workflow, from sample preparation to genomic profiling and data interpretation:

Sample technologies: New instruments and kits highlighting Parse single-cell solutions

QIAsymphony Connect: The upcoming IVD QIAsymphony Connect will support oncology workflows in laboratories around the world. This scalable automation platform for clinical molecular testing builds on over 3,300 placements of the established QIAsymphony system to automate IVD sample extraction, improve laboratory productivity, enhance sample traceability and process safety and deliver highly concentrated nucleic acid for sensitive assays. As molecular testing expands across oncology and other applications, QIAsymphony Connect will help laboratories standardize complex workflows while reducing hands-on time and supporting reproducible, high-quality results.
QIAsprint Connect: Following its launch at the SLAS 2026 meeting in February, QIAsprint Connect for research use only is now progressing through commercialization as QIAGEN’s new high-throughput automation platform for research laboratories. The compact benchtop system enables automated purification of up to 192 DNA or RNA samples per run, supports validated and customizable workflows, and helps laboratories scale sample processing while reducing plastic use and packaging volume.

Evercode single-cell analysis: Parse Biosciences, a QIAGEN company, will highlight at AACR (Free AACR Whitepaper) its Evercode Whole Transcriptome portfolio, including the recently launched v4 kit with higher cell recovery, higher sensitivity and shorter workflow with lower sequencing budget. Parse will also showcase the Evercode Whole Transcriptome FFPE kit, now shipping after the successful completion of an early access program with select partners. The Evercode WT FFPE enables unbiased whole transcriptome single cell RNA sequencing of millions of nuclei from FFPE-preserved tissues using Parse’s novel split-pool combinatorial barcoding method.

Genomic profiling:New QIAseq research panels for use on next-generation sequencers (NGS)
QIAseq xHYB HRD Panel: Developed with Myriad Genetics, the QIAseq xHYB HRD Panel is designed to support research into homologous recombination deficiency as an important cancer biomarker for research applications. The assay combines QIAGEN’s hybrid capture technology with Myriad analytics to support assessment of genomic instability, and has shown high concordance with the Myriad myChoice CDx HRD assay.
QIAseq xHYB Trinity DNA/RNA Kit: This new kit enables comprehensive genomic profiling from DNA, RNA or both in a single research workflow using the AVITI platform from Element Biosciences. Designed for use with Element’s Trinity sequencing workflow, it helps streamline target enrichment through a shorter hybridization step, fewer manual cleanup steps and no post-enrichment PCR, reducing hands-on time while supporting high on-target rates and confident variant detection for research applications.

Data interpretation: New AI-grounding platform for unified drug discovery support for research purposes
QIAGEN Discovery Platform: QIAGEN Digital Insights, the bioinformatics business of QIAGEN, will introduce the QIAGEN Discovery Platform at AACR (Free AACR Whitepaper) as an AI-grounding solution for drug discovery. The platform is designed to bring together biological knowledge, omics data and advanced analytics to support oncology research, with future implementation of AI functions and integration with downstream AI analysis. The platform will be presented through demonstrations and spotlight sessions at the AACR (Free AACR Whitepaper) meeting.
To learn more about QIAGEN’s Sample to Insight portfolio, visit Booth #3547 at the AACR (Free AACR Whitepaper) Annual Meeting 2026 in San Diego from April 17–22, or go to www.qiagen.com/oncology-meeting.

(Press release, Qiagen, APR 16, 2026, View Source [SID1234664437])